Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf. [Yahoo! Finance]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Yahoo! Finance
for avexitide has finished screening and expects top-line results in the third quarter, using Level II/III hypoglycemia endpoints with a run-in to confirm qualifying event frequency. Avexitide is a first-in-class GLP-1 receptor antagonist targeting post-bariatric hypoglycemia (an estimated ~160,000 U.S. patients) with no approved therapies; prior trials showed consistent, significant reductions in hypoglycemia and supported FDA Breakthrough Therapy designation. Amylyx is expanding the program with a long-acting antagonist (lead candidate AMX0318 in IND-enabling studies aiming for clinic entry next year) and is advancing a Wolfram syndrome program that has shown increased C-peptide and other positive signals in an ongoing 12-patient study. Interested in Amylyx Pharmaceuticals, Inc.? Here are five stocks we like better. 3 small-cap biotechs with potential breakthroughs in 2024 Amylyx Pharmaceuticals (NASDAQ:AMLX) co-CEO Justin Klee discussed the company's lead endocrine progra
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Amylyx Pharmaceuticals (AMLX) had its price target raised by Guggenheim from $25.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- Amylyx Pharmaceuticals (AMLX) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=AMLX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sMarketBeat
- Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals (AMLX) had its price target raised by HC Wainwright from $28.00 to $34.00. They now have a "buy" rating on the stock.MarketBeat
- Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout [Yahoo! Finance]Yahoo! Finance
AMLX
Earnings
- 3/3/26 - In-Line
AMLX
Sec Filings
- 3/9/26 - Form 4
- 3/9/26 - Form 4
- 3/9/26 - Form 4
- AMLX's page on the SEC website